The Science Behind the Headlines
The free Biotech Primer WEEKLY explains the science behind today’s headlines. Delivered each Thursday directly to your inbox. Subscribe to The WEEKLY today.
Stump The Clumps: New Drugs To Treat Amyloidosis We at the WEEKLY aim to keep you up on the coolest, latest innovations in biotech. Bonus: we might also help you win Jeopardy. Ready? The category is Rare Diseases for $1,000. The clue is “Amyloidosis.” Ding ding ding!...read more
The Science of Biotech
The most recent Biotech Primer WEEKLY looked at a particularly productive new area of medicine courtesy of our own tiny personal zoo: the microbiome. We considered how resetting a person’s microbiome with a fecal matter transplant (FMT) aka bacteriotherapy can heal such troubling conditions as antibiotic-resistant C. difficile infections and inflammatory bowel disease (IBD). Thankfully for the millions suffering from these health conditions, acceptance of FMTs is growing. Now the research community is turning its attention to the specific components behind the microbiome’s healing potential. Several biotech companies are already developing more precisely-defined therapeutics. This work will foster better quality control and more comfortable formulations. Who wouldn’t prefer swallowing a capsule to undergoing an enema or colonoscopy?read more
Wading Deeper Into Biomanufacturing Last week, we began our exploration of biomanufacturing--defining terms, introducing the different types of cells used in production, and explaining how manufacturers create cell banks to provide raw materials for the medicines some...read more